ImplicitBioscience

Our pioneering work in cardioimmunology has captured national attention, with The Australian today reporting on the publication of our foundational cardiology data in the Journal of the American College of Cardiology (JACC). Take a look: bit.ly/49kAsYB

JOURNAL ARTICLE | @MedicineLWW has published a report of the first safety and biomarker study of #IC14 in patients with #ALS #MND. See it here 👉bit.ly/IMP_JournalArt… #MedicalResearch #biotech #pharma #ImplicitBioscience

We’re proud to share a feature story written by a respected US biotechnology commentator. It captures the fascinating history of #ImplicitBioscience – including our why, how and what next – as we test the full capabilities of our IC14 antibody 👉 bit.ly/IMP_FeatureSto… #biotech

@sunriseon7 Thanks for having our CSO Professor Ian Frazer on the show this morning - we really appreciate your support 🙌

A new drug developed by Australian researchers is being trialled on coronavirus patients in the United States. The game-changing treatment has the potential to treat more than 500 illnesses including COVID-19, motor neurone disease, Lou Gehrig's disease and Parkinson's

Did you see the @couriermail today? @janellehmiles explains how #IC14 works 👉 bit.ly/IMP_CourierMail

Thank you to @abcbrisbane for inviting our CSO Prof Ian Frazer into studio today for an interview with @Loretta_Ryan and @zonca (and a later cross on @abcnews 24 too) - see here 👉 bit.ly/IMP_ABCOnline

Our CSO Professor Ian Frazer appeared on @sunriseon7 this morning to discuss the commencement of our Phase 2 clinical trials for #IC14 in #coronavirus patients in the US. Take a look 👉

CLINICAL MILESTONE | Our lead therapeutic candidate, #IC14 will be tested as part of a Phase 2 clinical trial in COVID-19 patients in US hospitals. We're hosting a media call at @TRI_info today, learn more 👉 bit.ly/IMP_Covid-19Tr… @NIAIDNews #research #biotech #lifesciences